publication . Other literature type . Article . 2016

The sphingosine-1-phosphate receptor: A novel therapeutic target for multiple sclerosis and other autoimmune diseases.

Yang Mao-Draayer; Jeffrey Sarazin; David Fox; Elena Schiopu;
Open Access English
  • Published: 23 Nov 2016
Abstract
Abstract Multiple sclerosis (MS) is a prototype autoimmune disease of the central nervous system (CNS). Currently, there is no drug that provides a cure for MS. To date, all immunotherapeutic drugs target relapsing remitting MS (RR-MS); it remains a daunting medical challenge in MS to develop therapy for secondary progressive MS (SP-MS). Since the approval of the non-selective sphingosine-1-phosphate (S1P) receptor modulator FTY720 (fingolimod [Gilenya®]) for RR-MS in 2010, there have been many emerging studies with various selective S1P receptor modulators in other autoimmune conditions. In this article, we will review how S1P receptor may be a promising therap...
Subjects
free text keywords: Article, Receptor modulator, Multiple sclerosis, medicine.disease, medicine, Psoriasis, Immunology, business.industry, business, Sphingosine-1-phosphate receptor, Polymyositis, Systemic lupus erythematosus, Fingolimod, medicine.drug, Autoimmune disease
Related Organizations
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue
publication . Other literature type . Article . 2016

The sphingosine-1-phosphate receptor: A novel therapeutic target for multiple sclerosis and other autoimmune diseases.

Yang Mao-Draayer; Jeffrey Sarazin; David Fox; Elena Schiopu;